Talecris backers design a $1 billion IPO

Two big private equity firms appear to be behind the decision to push a $1 billion IPO for Talecris Biotherapeutics. Talecris uses plasma to make new therapies for chronic illness. Cerberus Capital Management and Ampersand Ventures, which arranged the buyout of Talecris from Bayer, seem to be betting on cashing out of the debt-heavy company before the stock market weakens too much.

It remains to be seen if investors are still willing to buy into a company that has been pushed hard by equity groups. Talecris has more than doubled its payroll in the past two years, significantly raising expenses. If the IPO is successful, it would also mark a major coup for the industry, which has seen a string of biotech IPOs pulled recently.

- read the report from the News & Observer

ALSO: Case in point: Quark Pharmaceuticals couldn't make the IPO leap. Report

Related Articles:
A closer look at the biotech IPO. Report
Will private equity get a crush on biotechnology? Report
Biotech IPOs losing their attraction. Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.